January 30, 2019 10:56 AM EST
News Briefing

Pro­to­cols: No­var­tis CEO is still map­ping out San­doz's fu­ture; But Swiss gi­ant is gung ho on all things dig­i­tal

John Carroll

Editor & Founder

→ No­var­tis CEO Vas Narasimhan is rais­ing some eye­brows to­day as he dis­cuss­es the fu­ture of San­doz, the phar­ma gi­ant’s big gener­ics unit. “We con­sid­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times